Rx/Reimbursement Adult Incontinence in Australia

April 2026

In 2025, rx/reimbursement adult incontinence experienced strong growth of 9% to reach AUD125 million in current terms. Affordability defined rx/reimbursement adult incontinence in 2025, as the Australian government maintained stability through a policy of strict inflation-linked indexation. The Continence Aids Payment Scheme (CAPS)'s annual benefit was increased in July 2025, matching the cost-of-living increase and ensuring that recipients’ purchasing power was preserved in the face of rising m

USD 1,195
Request More Information

Delivery:

Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).

This report comes in PDF with additional info in Excel included.

Overview:

Understand the latest market trends and future growth opportunities for the Rx/Reimbursement adult incontinence industry in Australia with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.

Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.

If you're in the Rx/Reimbursement adult incontinence industry in Australia, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.

The Rx/Reimbursement adult incontinence in Australia report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volume and value sizes, company and brand market shares
  • Five year forecasts of market trends and market growth
  • Robust and transparent research methodology, conducted in-country

This report answers:

  • What is the market size of Rx/Reimbursement adult incontinence in Australia?
  • Which are the leading brands in Rx/Reimbursement adult incontinence in Australia?
  • How are products distributed in Rx/Reimbursement adult incontinence in Australia?
  • How is the rise of e-commerce changing the retail and competitive landscape?
  • How has COVID-19 impacted demand? Where have sales increased due to stockpiling amidst national lockdown?
  • How have enforced home seclusion and social distancing measures following COVID-19 changed usage patterns for Rx/Reimbursement adult incontinence products?
  • Where is future growth expected to be most dynamic?
  • How important will sustainability and recycling be in generating future growth?

Rx/Reimbursement Adult Incontinence in Australia - Category analysis

Key Data Insights

Government Indexation Preserves Purchasing Power for Incontinence Recipients
Chart 1 Key Industry Trends for Rx/Reimbursement Adult Incontinence
Government Indexation Preserves Purchasing Power for Incontinence Recipients
Chart 2 CAPS Indexation Maintains Access
Independence Australia Streamlines Ordering with Direct Payment Integration
Chart 3 Direct-to-Supplier Payment Integration Under CAPS
Chart 4 Value Sales 2020-2030
Chart 5 Volume Sales 2020-2030
Suppliers to Align Pricing and Digital Systems to Secure Funding Access
Improved Digital Infrastructure to Be Integral for Future Sales
Government Oversight and Compliance Frameworks to Shape Supplier Participation
Chart 6 Forecast Value Sales 2020-2030
Independence Australia Streamlines Funding Access through Digital Delivery
Chart 7 Economic Context for Rx/Reimbursement Adult Incontinence
Chart 8 Real Gdp Growth 2020-2030
Chart 9 Inflation 2020-2030
Chart 10 Consumer Context for Rx/Reimbursement Adult Incontinence
Chart 11 Population 2020-2030
Chart 12 Consumer Expenditure 2020-2030
Chart 13 Population by Generation 2025

Tissue and Hygiene in Australia - Industry Overview

Affordability Significantly Influences Tissues and Hygiene Performance

Key Data Insights

Chart 14 Key Industry Trends for Tissue and Hygiene
Affordability Significantly Influences Tissues and Hygiene Performance
Chart 15 Woolworth's Affordability Expansion
Sustainability Shifts From a Rising Trend to a Government Requirement Amid Eco-Regulations
Chart 16 Essity Debuts Geothermal-Powered Tissue Production
Digital-First Hygiene Supported by the Mainstream Adoption of E-Commerce
Chart 17 Value Sales 2020-2030
Chart 18 Value Sales by Category 2025
Convenience, Consistency and an Ageing Population Set to Boost Incontinence Sales
Automated Replenishment and Operational Transparency to Drive Loyalty
Trust and Authenticity to Influence Thoughtful Spending Habits
Chart 19 Analyst Insight for Tissue and Hygiene
Chart 20 Forecast Value Sales 2020-2030
Chart 21 Forecast Value Sales by Category 2025-2030
Kimberly-Clark Pty Ltd Defends Lead as Challengers Gain through Digital and Sustainability
Emerging Brands Cleanlife and Kine Australia Grow Awareness through Innovation
Femlibre's Free Menstrual Care Model Reshapes Expectations
Chart 22 Company Shares 2025
Chart 23 Brand Shares 2025
Everyday Essentials Drive Grocery Retailer Dominance
Emerging Brands and Collaborations Set New Standard, Impacting Purchasing Decisions
Chart 24 Retail Channels 2020-2025
Chart 25 Economic Context for Menstrual Care
Chart 26 Real Gdp Growth 2020-2030
Chart 27 Inflation 2020-2030
Chart 28 Consumer Context for Menstrual Care
Chart 29 Population 2020-2030
Chart 30 Consumer Expenditure 2020-2030
Chart 31 Population by Generation 2025

Country Reports Disclaimer

Rx/Reimbursement adult incontinence

To qualify for reimbursement, typically a note from a physician is required (a “prescription”) indicating that the patient is in need of incontinence supplies. Depending on the local system in place, supplies are then either shipped directly to consumer home by a designated service or a consumer has to pick up products at a pharmacy. Please be advised that services and routes to consumers can vary even within the same country and vary by state/region. Some countries provide reimbursement through income tax deductions. If this is the case in your market, we EXCLUDE this type of reimbursement from our Rx/Reimbursement coverage as it would be impossible to track. Additionally, consumers would have already purchased the products in retail before claiming tax deductions, and as such the products have already been counted as retail sales. The same logic applies to institutional sales. If a nursing home purchased adult incontinence products from a distributor/manufacturer for distribution to its patients/residents, these products would be included as AFH adult incontinence in our coverage, even though sometimes patients might claim healthcare deductions for costs of stay at a nursing home.

See all of our definitions
Share:

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This report originates from Passport, our Rx/Reimbursement adult incontinence research and analysis database.

NEW REPORT GUARANTEE

If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extraction Free!